The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

The agritech industry is editing plant genomes to feed a growing population, expand the produce aisle, and make tastier, more convenient food products.

As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

After two decades of failure, novel scientific insights and technical progress are spurring meaningful innovation in the field.

The IoT can link up many facets of research—from laboratory equipment to ideas—but scientists must be ready for the questions its implementation could raise.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

From basic research in academic labs to Phase 3 clinical trials, myriad efforts are underway to divorce opioids' pain-relieving potential from their undesirable downsides.